Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Study Objectives: There is increasing interest in the frequency and nature of comorbidities in patients with obstructive lung disease: COPD and asthma. We aimed to quantify baseline rates of comorbidities in COPD and asthma patients and to compare the risks to the general population.
Design, Setting, And Participants: Within the UK General Practice Research Database, we compared incident patients with COPD (n = 2,699) and asthma (n = 7,931) physician diagnosed in 1998 with age, gender, time, and practice-matched cohorts. Rates were calculated and relative risks (RRs) were estimated for comorbidities in major organ systems and selected medical events of a priori interest.
Measurements And Results: In both COPD and asthma, the total sum of diagnoses related to major organ systems was higher than in their matched population controls. Among incident COPD patients, a frequency > 1% within the first year after diagnosis was observed for angina, cataracts, bone fractures, osteoporosis, pneumonia, and respiratory infections, the highest being angina with 4.0%. Compared to the non-COPD cohort, COPD patients were at increased risk for pneumonia (relative risk [RR] = 16.0), osteoporosis (RR = 3.1), respiratory infection (RR = 2.2), myocardial infarction (RR = 1.7), angina (RR = 1.7), fractures (RR = 1.6), and glaucoma (RR = 1.3) [all p < 0.05]. Of note, 2.0% of COPD patients had cataracts recorded, but this rate was no different than that of the non-COPD cohort (RR = 0.9). Among incident asthma patients, the occurrence of events was generally lower, likely due to the younger age distribution, except for 4.0% with respiratory infection (RR = 1.84) and 1.7% with fractures (RR = 1.5). Angina prevalence was 0.7% in the asthma cohort and 1.4 times more common than in patients without asthma.
Conclusion: COPD and asthma are conditions associated with many comorbidities, albeit asthma to a lesser extent than COPD, which had not been systematically reviewed before. Baseline rates of cardiovascular-, bone-, and other smoking-related conditions are high.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1378/chest.128.4.2099 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Formoterol, a clinically approved drug, inhibits ferroptosis by suppressing lipid peroxidation and attenuates APAP-induced acute liver injury.
Chem Biol Interact
September 2025
College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong Normal University, Jinan, 250014, China. Electronic address:
Ferroptosis is an iron-dependent form of regulated cell death characterized by lethal lipid peroxidation and implicated in various human diseases. Despite intensive research, clinically applicable ferroptosis inhibitors remain unavailable. In this study, we identify formoterol, a β-adrenergic agonist widely used to treat asthma and COPD, as a potent and selective ferroptosis inhibitor through scaffold-based screening of FDA-approved drugs.
View Article and Find Full Text PDFAir pollution and diseases: signaling, G protein-coupled and Toll like receptors.
Pharmacol Ther
September 2025
Department of Molecular Pharmacology, University of Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, GRIAC, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address:
Air pollution is a significant public health issue that impacts lung health, particularly in vulnerable populations such as children, the elderly, and individuals with pre-existing respiratory conditions. Both natural and anthropogenic sources of air pollution give rise to a variety of toxic compounds, including particulate matter (PM), ozone (O₃), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), and polycyclic aromatic hydrocarbons (PAHs). Exposure to these pollutants is strongly associated with the development and exacerbation of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF).
View Article and Find Full Text PDFAssociations between PM from prescribed burning and emergency department visits in 11 Southeastern US states.
Environ Int
September 2025
Department of Environmental Health, Boston University School of Public Health, 715 Albany Street, Boston, MA 02118, USA. Electronic address:
Longer, more severe wildfire seasons are becoming the norm in fire-prone areas. Prescribed burning is a tool used to mitigate wildfire spread. However, prescribed burning also contributes to air pollution, including PM (particulate matter with aerodynamic diameter <= 2.
View Article and Find Full Text PDFAssessing inpatient formulary-driven inhaler use in presumed Group B chronic obstructive pulmonary disease.
J Am Pharm Assoc (2003)
September 2025
WVU Medicine - WVU Hospitals; Morgantown, WV; West Virginia University School of Pharmacy; Morgantown, WV.
Background: Long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA) combination maintenance therapy is recommended for patients with Group B chronic obstructive pulmonary disease (COPD) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Exposure to inhaled corticosteroids (ICS) in these patients may increase adverse effects without adding clinical benefit. Inpatient formulary limitations may facilitate unnecessary exposure to ICS and ICS-associated adverse events while hindering the use of optimal LAMA/LABA inhaler therapy in Group B COPD patients.
View Article and Find Full Text PDFInhaled Cannabis, Asthma, and Chronic Obstructive Pulmonary Disease: A Population-Based Cross-Sectional Study of n = 379,049.
J Gen Intern Med
September 2025
Center for Data to Discovery and Delivery Innovation (3DI), San Francisco VA Health Care System, San Francisco, CA, USA.
Background: Cannabis may cause chronic pulmonary disease. Prior studies have been limited by low cannabis exposure, lack of data on tobacco cigarettes, and/or limited numbers of those without tobacco cigarette use.
Objective: To examine whether inhaled cannabis associated with asthma and chronic obstructive pulmonary disease, independent of tobacco cigarettes.